A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.
María‐Victoria Mateos(Hospital Clínico San Carlos), Jesús F. San Miguel(Clinica Universidad de Navarra), Joan Bladé(Hospital Clínic de Barcelona), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Alejandro Martı́n(Instituto de Investigación Biomédica de Salamanca), Norma C. Gutiérrez(Universidad de Salamanca), Albert Oriol(Institut Català d'Oncologia), María José Terol(Hospital Clínico Universitario de Valencia), María Teresa Cibeira(Boston University), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Enrique Garcíá Bengoechea(Biogipuzkoa Health Research Institute), José García‐Laraña, Raquel de Paz(Hospital Universitario La Paz), Luis Palomera(Hospital Clínico Universitario Lozano Blesa), José-Luis Bello(Complejo Hospitalario Universitario de Santiago), Felipe de Arriba(Hospital General Universitario Morales Meseguer), Rafael Martínez(Hospital Clínico San Carlos), Juan José Lahuerta(Research Institute Hospital 12 de Octubre)
Cited by 45
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k